The UCI Health Chao Family Comprehensive Cancer Center is now enrolling patients in these featured clinical trials.

To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at ucstudy@uci.edu or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

**Brain and nervous system**

A pivotal, randomized, open-label study of Optune® (tumor treating fields) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma (EF-32) (UCI-20-65)

*For more information, contact principal investigator Scott G. Turner, MD*

A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1- and IDH2-mutant advanced solid tumors (ETCTN-10129)

*For more information, contact principal investigator Xiao-Tang Kong, MD*

**Breast**

A randomized phase 1/2 trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) vs. fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor-positive, HER2-negative metastatic breast cancer (FAC vs. FA) (ETCTN-10287)

*For more information, contact principal investigator Ritesh Parajuli, MD*
A phase 1b/2, two-part, open-label study to assess the safety and antitumor activity of zanidatamab (ZW25) in combination with evorpacept (ALX148) in advanced HER2-expressing cancer (UCI-21-57/ZWI-ZW25-204)

For more information, contact principal investigator Ritesh Parajuli, MD

Gastrointestinal

A phase 2, single-arm study of M6620 in combination with irinotecan in patients with progressive TP53-mutant gastric and gastroesophageal junction cancer (ETCTN-10211)

For more information, contact principal investigator Farshid Dayyani, MD

A phase 2 study of neoadjuvant nivolumab plus ipilimumab and short-course radiation in MSI-H/dMMR locally advanced rectal adenocarcinoma (ECOG-EA2201)

For more information, contact principal investigator May Cho, MD

Genitourinary

A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone (AA-P) vs. abiraterone acetate and prednisone in subjects with deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) (UCI-20-146)

For more information, contact principal investigator Edward Uchio, MD

Parallel phase 3 randomized trials for high-risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation (PREDICT-RT) (NRG-GU009)

For more information, contact principal investigator Steven N. Seyedin, MD

A phase 2 study of olaparib (AZD2281) in patients with metastatic/advanced urothelial carcinoma and other genitourinary tumors with DNA-repair defects (ETCTN-10144)

For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD

Gynecologic oncology

A phase 3 randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/AVBS00-OC-004)

For more information, contact principal investigator Fabio Cappuccini, MD
A phase 1a/b study to evaluate the safety and tolerability of ETC-1922159 as a single agent and in combination with pembrolizumab in advanced solid tumors (UCI-20-111/D3-002)
For more information, contact principal investigator Krishnansu Tewari, MD

**Head and neck**

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (NRG-HN001)
For more information, contact principal investigator Rupali Nabar, MD

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin + docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)
For more information, contact principal investigator Rupali Nabar, MD

**Hematologic malignancies**

A phase 1/2, open-label, multicenter trial to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (UCI-21-19/MB106-CD20-001)
For more information, contact principal investigator Susan O’Brien, MD

A phase 2 study of Descartes-08 consolidation treatment in patients with high-risk multiple myeloma who have residual disease after induction therapy (UCI-21-02/DC-08-B)
For more information, contact principal investigator Stefan O. Ciurea, MD

**Hepatobiliary**

A phase 1 study of anetumab ravtansine in combination with either anti-PD-1 antibody or anti-CTLA4 + anti-PD-1 antibodies, or anti-PD-1 antibody + gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (ETCTN-10208)
For more information, contact principal investigator Farshid Dayyani, MD

A randomized phase 2 trial of postoperative adjuvant capecitabine and temozolomide vs.
observation in high-risk pancreatic neuroendocrine tumors (SWOG-S2104)

For more information, contact principal investigator Jennifer Valerin, MD

Lung

A phase 1b study evaluating the safety, tolerability, pharmacokinetics and efficacy of bemarituzumab monotherapy and in combination with docetaxel in subjects with squamous-cell non-small-cell lung cancer (FORTITUDE-201) (UCI-21-218/20210102)

For more information, contact principal investigator Misako Nagasaka, MD


For more information, contact principal investigator Misako Nagasaka, MD

Skin

A phase 1/2, first-in-human, multipart, open-label, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF6002 as a monotherapy and in combination with nivolumab in patients with locally advanced or metastatic solid tumor and expansion in selected indications (UCI-21-40/DF6002-001)

For more information, contact principal investigator Jennifer Valerin, MD

A phase 2 study of talimogene laherparepvec (T-VEC) and radiation in localized soft tissue sarcoma (ETCTN-10056)

For more information, contact principal investigator Jeremy P. Harris, MD